Skip to Content
MDPIMDPI

Advanced

Sci. Pharm.Scientia Pharmaceutica
PDF
  • Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
  • Abstract
  • Open Access

16 April 2009

1 Page

QSAR, HQSAR and GRIND Studies on a Set of Heterocyclic Propafenone-Type Inhibitors of P-Glycoprotein

,
,
and
1
Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, A-1090, Vienna, Austria
2
Department of Drug and Natural Product Synthesis, University of Vienna, Althanstraße 14, A-1090, Vienna, Austria
*
Author to whom correspondence should be addressed.
Sci. Pharm.2009, 77(7), 201;https://doi.org/10.3797/scipharm.oephg.21.PO-02
Version Notes
Order Reprints

Abstract

P-Glycoprotein (P-gp) is a member of the ABC (ATP binding cassette) super-family of transport proteins, which in addition to their physiological role in tissue protection, actively extrude a large variety of therapeutically administered drugs from the malignant cells and thus are responsible for multiple drug resistance (MDR) in cancer patients [1]. Since the discovery of P-gp more than 30 years ago many studies have shown that MDR can be reversed by the use of inhibitors, often denoted as MDR modulators.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Condor@Univie – a Distributed System Web Portal for Rigid & Flexible Ligand-Protein Docking
Previous
Ligand Based Screening Tools for Insulin Receptor Activating Compounds
Next